retatrutide clinical trial results 2024 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation The Thriving Black Market for

Yu C, Gupta J, Chen JF, Yin HH

Energy can dip early in treatment

(Source: Long-term GLP-1 safety review, June 2026) There Is No Evidence Supporting a Hard Time Limit on Treatment A frequent patient concern is that GLP-1s cannot be safe indefinitely

Although between-group differences were not statistically significant, the 10 mg group exhibited clinically meaningful improvements in HbA1c and a greater trend toward weight loss

We were quite surprised by the strength of the association between GLP-1 medication use and the lower risk of developing macular degeneration, says Benjamin Young, MD, a corresponding author and an assistant professor of ophthalmology at OHSU Health in Portland, Oregon

Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease